NEW YORK (GenomeWeb) – Biocept today announced a new collaboration with University of California, San Diego Moores Cancer Center aimed at determining the clinical utility of the company's liquid biopsy technology in detecting biomarkers present in circulating tumor cells and cell-free DNA in the blood of non-small cell lung cancer patients.

Biocept's OncoCEE LU platform and CEE-Selector technology allow highly sensitive, quantitative blood-based detection of cancer mutations, which can be used by clinicians to inform personalized treatment decisions based on genomic information.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
13
Sponsored by
Horizon Discovery

This webinar will discuss development and validation of an assay for detection of microsatellite instability (MSI) based on a novel set of biomarkers.